Intercell AG (VSE: ICLL) announced its financial results for Q3 2012 and provided an operational update.
- IXIARO®/JESPECT® - product sales growth trend continues despite lower than expected product sales of EUR 3.5m in Q3 2012
- U.S. military places largest IXIARO® order to date in Q4 2012
- Net loss for Q3 2012 slightly decreased by 2.8% to EUR 7.5m
For details please see the full Q3 report here.
We cordially invite you to listen to conference call via webcast:
Wednesday, November 7, 2012
2 p.m. CET (1 p.m. BST / 8 a.m. EST)
Chairperson: Thomas Lingelbach, CEO Intercell AG
You can access this webcast live on iOS- and Android-powered mobile devices, including iPad. No app or special software is required.